Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DZIP1L (Cilium assembly protein DZIP1L) is a zinc finger and coiled-coil domain containing protein that localizes to centrioles, basal bodies, and the ciliary transition zone, playing an essential role in the formation and architecture of primary cilia[1][2][4][5]. Mutations in DZIP1L are a genetic cause of autosomal recessive polycystic kidney disease (ARPKD), affecting the proper distribution and function of PKD proteins (polycystin-1 and polycystin-2) at the ciliary membrane. DZIP1L modulates the gating function of the transition zone/transition fibers, which controls entry of soluble and membrane proteins into cilia[1][2][5]. Deficiency leads to severe kidney phenotypes including polycystic changes, hypertension, and renal failure[1]. DZIP1L does not currently have established pharmacological modulators or known drug interactions, but its gene and protein serve as important clinical biomarkers for genetic diagnosis and mechanistic investigation of ARPKD and other ciliopathies[1][2][5].
Not applicable (no drugs directly targeting DZIP1L have mechanism of action described in the literature).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cilium assembly protein DZIP1L (DZIP1L).